Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Evotec SENASDAQ: EVO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow grows to €24.21M
Q1 FY2026 depreciation & amortization was €24.21M, compared with €0 a year earlier. Trailing-twelve-month depreciation & amortization was €49.53M. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Depreciation & amortization amounted to 12.6% of revenue in FY2025, down 0.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly depreciation & amortization holds near €24.21M or moves back toward the trailing-twelve-month quarterly average of €12.38M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the cash flow
- Latest · FY2025
- 95.55M EUR
- Year-over-year change
- -6.0%
- 4-year CAGR
- +9.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.55M | -6.0% |
| FY2024 | 2024-12-31 | 101.62M | +9.3% |
| FY2023 | 2023-12-31 | 92.98M | +11.8% |
| FY2022 | 2022-12-31 | 83.2M | +23.1% |
| FY2021 | 2021-12-31 | 67.61M | — |
Depreciation & Amortization vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +95.7% is the highest of 10, against a peer median of +11.8%.
- Depreciation & amortization amounts to 6.6% of revenue for EVO, versus a peer median of 7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $370.85M USD | -0.4% | +10.7% | 14.7% | |
| LTM Feb 2026 | $107.17M USD | -41.2% | -2.0% | 9.1% | |
| LTM Mar 2026 | $91.19M USD | +11.8% | -0.2% | 12.4% | |
| LTM Sep 2026 | $56.52M USD | -7.7% | -12.9% | 9.1% | |
| LTM Mar 2026 | €49.53M EUR | +95.7% | +4.7% | 6.6% | |
| LTM Mar 2026 | $39.88M USD | +23.2% | +22.9% | 7.1% | |
| LTM Mar 2026 | $20.35M USD | +25.1% | +75.1% | 7.6% | |
| LTM Mar 2026 | $6.43M USD | +26.3% | +11.3% | 1.0% | |
| LTM Sep 2026 | $5.86M USD | -7.7% | +11.5% | 2.2% | |
| LTM Sep 2026 | €483K EUR | +19.4% | +39.9% | — | |
| LTM Sep 2026 | $0 USD | — | +72.0% | 0.0% | |
| Peer median (excluding EVO) | — | +11.8% | +11.4% | 7.6% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Depreciation & Amortization | 67.61M | 83.2M | 92.98M | 101.62M | 95.55M |
| Deferred Income Tax | 5.07M | 21.7M | 3.32M | 2.1M | 14.11M |
| Stock-Based Compensation | 7.81M | 9.92M | 9.63M | 5.04M | 0 |
| Change in Working Capital | (2.28M) | 105.29M | (9.94M) | (68.21M) | (58.4M) |
| Accounts Receivables | (48.03M) | (53.68M) | 0 | 0 | (27.6M) |
| Inventory | (11.65M) | (4.41M) | 0 | 0 | (9.18M) |
| Accounts Payables | 31.34M | 24.55M | 0 | 0 | (7.02M) |
| Other Working Capital | 26.06M | 138.83M | (9.94M) | (68.21M) | (14.61M) |
| Other Non-Cash Items | (171.47M) | 161.37M | 24.37M | 173.75M | 39.11M |
| Operating Cash Flow | 122.24M | 205.81M | 36.44M | 18.22M | (9.06M) |
| Capital Expenditures | (118.94M) | (181.35M) | (216M) | (132.24M) | (69.68M) |
| Acquisitions (Net) | (21.09M) | (83.82M) | (20.16M) | 42.78M | 213.76M |
| Purchases of Investments | (123.7M) | (355.82M) | (48.39M) | (29.39M) | (13.42M) |
| Sales of Investments | 27.25M | 205.17M | 260.36M | 35.67M | 38.87M |
| Other Investing Activities | (7.38M) | 3.03M | 8.22M | (2.78M) | 0 |
| Investing Cash Flow | (243.86M) | (412.8M) | (13.29M) | (71.19M) | 159.86M |
| Debt Repayment | 14.77M | (53.11M) | 84.6M | (152.07M) | (6.96M) |
| Common Stock Issued | 404.32M | 355K | 0 | 0 | (1.27M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.67M) | (5.39M) | (12.63M) | (9.35M) | (22.71M) |
| Financing Cash Flow | 398.43M | (58.15M) | 71.96M | (161.42M) | (30.93M) |
| Effect of Forex Changes | (66K) | (19.04M) | 644K | 9.87M | 28.46M |
| Net Change in Cash | 276.75M | (284.17M) | 95.75M | (204.52M) | 148.32M |
| Free Cash Flow | 3.29M | 24.46M | (179.56M) | (114.02M) | (78.74M) |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.